Other rat sarcoma (RAS) mutations (specifically KRAS exon 3 and 4, and neuroblastoma (N]RAS) and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations may similarly reduce the benefit of anti-EGFR therapies. This evidence concerns the gene BRAF and neuroblastoma.